Breaking News

Catalent to Acquire Bone Therapeutics’ Cell Therapy Mfg. Facility

Expands cell therapy capabilities and advanced clinical and commercial supply, and creates an integrated European CoE.

By: Contract Pharma

Contract Pharma Staff

Catalent has signed an agreement with Bone Therapeutics to acquire its cell therapy manufacturing subsidiary, Skeletal Cell Therapy Support SA (SCTS), including all of its assets located in Gosselies, Belgium. Catalent will purchase the shares of SCTS, currently held by Bone Therapeutics, which owns and operates a purpose-built CGxP facility of approximately 41,000 square-foot, including its related quality control and product development labs, warehouse, grade C and B cleanrooms and equipme...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters